Huntsman Corporation 10-Q Summary: Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025, for Huntsman Corporation and its wholly-owned subsidiary, Huntsman International LLC. Huntsman is a global manufacturer of diversified organic chemical products operating in three segments: Polyurethanes, Performance Products, and Advanced Materials. The company operates globally, with significant exposure to industrial and building product markets.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) |
|---|---|---|
| Total Revenues | $2,868 million | $3,044 million |
| Gross Profit | $383 million | $444 million |
| Operating Loss | $(78) million | $(4) million |
| Net Loss (Attributable to Huntsman Corp) | $(163) million | $(15) million |
| Diluted EPS (Loss) | $(0.94) | $(0.09) |
| Adjusted EBITDA | $146 million | $212 million |
| Free Cash Flow | $(52) million | $(100) million |
| Total Debt | $2,035 million | $1,835 million |
| Cash and Cash Equivalents | $399 million | $340 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 6% year-over-year, driven by lower average selling prices (particularly in Polyurethanes and Advanced Materials) and lower sales volumes (notably in Performance Products and Advanced Materials).
- Restructuring Costs: A significant driver of the operating loss was a $125 million charge for restructuring, impairment, and plant closing costs, compared to only $15 million in the prior year. This includes an $88 million charge in the Performance Products segment for the closure of the Moers, Germany facility and a $38 million charge in the Polyurethanes segment.
- Asset Acquisition Gains: The company recognized a $5 million gain on the acquisition of assets from the SLIC joint venture in 2025, compared to a $51 million gain in 2024.
- Legal Settlement Income: The company recognized $33 million of income related to the resolution of litigation against Praxair/Linde in the first quarter of 2025.
- Segment Performance: Adjusted EBITDA declined across all segments: Polyurethanes (-39%), Performance Products (-30%), and Advanced Materials (-15%).
Guidance, Outlook, and Risks
- Capital Expenditures: The company expects to spend between $180 million and $190 million on capital expenditures for the full year 2025.
- Debt Covenants: On May 23, 2025, the company amended its 2022 Revolving Credit Facility to increase the maximum permitted leverage ratio through December 31, 2026. This amendment also restricts the ability to make restricted payments (such as share repurchases) during this "Covenant Relief Period."
- Share Repurchases: No shares were repurchased under the company's program during the first half of 2025 due to the credit facility restrictions. Approximately $547 million remains authorized under the program.
- Tax Matters: The effective tax rate was impacted by the mix of income and losses across jurisdictions and the establishment of valuation allowances. A discrete tax expense of $8 million was recorded related to the Praxair litigation income.
- Market Risks: The company faces exposure to foreign currency exchange rates, interest rate fluctuations, and commodity price volatility. It utilizes derivative instruments to manage these risks.
Key Facts for Investor Verification
- Restructuring Impact: Verify the specific details and expected future cash outflows related to the $125 million restructuring charge, particularly the closure of the Moers facility and the timeline for the Polyurethanes segment optimization.
- Liquidity Position: Confirm the company's ability to service its debt obligations given the increased leverage ratio and the restriction on share repurchases until the covenant relief period ends.
- Segment Margins: Analyze the sustainability of the decline in gross margins across all three segments and the extent to which lower selling prices are driven by temporary market dynamics versus structural shifts.
- Legal Settlements: Monitor the finalization of the Praxair/Linde litigation award and any potential tax implications or appeals.
- Joint Venture Performance: Review the performance of unconsolidated affiliates, specifically the PO/MTBE joint venture in China, which contributed to a loss in equity income.